Vaccine Therapy in Patients with Renal Cell Carcinoma

European Urology

Volumn 55, Issue 6, 2009, Pages 1333-1344

  Van Poppel, Hein ^a   Joniau, Steven ^a   Van Gool, Stefaan W ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Active immunotherapy; Cancer vaccine; Dendritic cells; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; BETA INTERFERON; CARBONATE DEHYDRATASE IX; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; DENILEUKIN DIFTITOX; FREUND ADJUVANT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HEAT SHOCK PROTEIN 110; IMMUNOMODULATING AGENT; INTERLEUKIN 2; INTERLEUKIN 7; KEYHOLE LIMPET HEMOCYANIN; LARGE MULTIVALENT IMMUNOGEN; MONOCLONAL ANTIBODY G250; MONTANIDE ISA 51; PEPTIDE VACCINE; RENIALE; RETINOIC ACID; SRL 172; TUMOR ANTIGEN; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; VITESPEN;

ADJUVANT THERAPY; AUTOIMMUNE THYROIDITIS; CANCER IMMUNIZATION; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; DELAYED HYPERSENSITIVITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG SAFETY; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; KIDNEY CARCINOMA; LOW DRUG DOSE; MEDLINE; METASTASIS; NEPHRECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY CONTROL; REVIEW;

CANCER VACCINES; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE III AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG TOXICITY; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME; VACCINATION;

EID: 65049091110     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.01.043     Document Type: Review

References (54)

1. Ljungberg B., Hanbury D.C., Kuczyk M.A., et al. Renal cell carcinoma guideline. Eur Urol 51 (2007) 1502-1510
2. Schrader A.J., Varga Z., Hegele A., Pfoertner S., Olbert P., and Hofmann R. Second-line strategies for metastatic renal cell carcinoma: classics and novel approaches. J Cancer Res Clin Oncol 132 (2006) 137-149
3. Berntsen A., Geertsen P.F., and Svane I.M. Therapeutic dendritic cell vaccination of patients with renal cell carcinoma. Eur Urol 50 (2006) 34-43
4. Rini B.I., Rathmell W.K., and Godley P. Renal cell carcinoma. Curr Opin Oncol 20 (2008) 300-306
5. Haynes R.B., McKibbon K.A., Wilczynski N.L., Walter S.D., and Werre S.R. Optimal search strategies for retrieving scientifically strong studies of treatment from Medline: analytical survey. BMJ 330 (2005) 1179
6. Gouttefangeas C., Stenzl A., Stevanovic S., and Rammensee H.G. Immunotherapy of renal cell carcinoma. Cancer Immunol Immunother 56 (2007) 117-128
7. Frankenberger B., Regn S., Geiger C., et al. Cell-based vaccines for renal cell carcinoma: genetically-engineered tumor cells and monocyte-derived dendritic cells. World J Urol 23 (2005) 166-174
8. Galligioni E., Quaia M., Merlo A., et al. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: five-year results of a prospective randomized study. Cancer 77 (1996) 2560-2566
9. Schwaab T., Heaney J.A., Schned A.R., et al. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters. J Urol 163 (2000) 1322-1327
10. Dillman R., Barth N., Vandermolen L., et al. Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinoma. Cancer Biother Radiopharm 19 (2004) 570-580
11. Jocham D., Richter A., Hoffmann L., et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 363 (2004) 594-599
12. Dudek A.Z., Mescher M.F., Okazaki I., et al. Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma. Am J Clin Oncol 31 (2008) 173-181
13. Doehn C. Prolongation of progression-free and overall survival following an adjuvant vaccination with Reniale in patients with non-metastatic renal cell carcinoma: secondary analysis of a multicenter phase-III trial. Abstract presented at: the Deutscher Krebskongress; March 22-26, 2006; Berlin, Germany. http://www.egms.de/en/meetings/dkk2006/06dkk395.shtml.
14. Kubler H., and Vieweg J. Vaccines in renal cell carcinoma. Semin Oncol 33 (2006) 614-624
15. Simons J.W., Jaffee E.M., Weber C.E., et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 57 (1997) 1537-1546
16. Wittig B., Marten A., Dorbic T., et al. Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I/II trial. Hum Gene Ther 12 (2001) 267-278
17. Antonia S.J., Seigne J., Diaz J., et al. Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J Urol 167 (2002) 1995-2000
18. Tani K., Azuma M., Nakazaki Y., et al. Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings. Mol Ther 10 (2004) 799-816
19. Pizza G., De Vinci C., Lo Conte G., et al. Allogeneic gene-modified tumour cells in metastatic kidney cancer. Report II. Folia Biol (Praha) 50 (2004) 175-183
20. Moiseyenko V.M., Danilov A.O., Baldueva I.A., et al. Phase I/II trial of gene therapy with autologous tumor cells modified with tag7/PGRP-S gene in patients with disseminated solid tumors: miscellaneous tumors. Ann Oncol 16 (2005) 162-168
21. Fishman M., Hunter T.B., Soliman H., et al. Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma. J Immunother 31 (2008) 72-80
22. Ranieri E., Gigante M., Storkus W.J., and Gesualdo L. Translational mini-review series on vaccines: dendritic cell-based vaccines in renal cancer. Clin Exp Immunol 147 (2007) 395-400
23. Ernstoff M.S., Crocenzi T.S., Seigne J.D., et al. Developing a rational tumor vaccine therapy for renal cell carcinoma: immune yin and yang. Clin Cancer Res 13 (2007) 733s-740s
24. Tuyaerts S., Aerts J.L., Corthals J., et al. Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol Immunother 56 (2007) 1513-1537
25. Holtl L., Rieser C., Papesh C., et al. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol 161 (1999) 777-782
26. Marten A., Flieger D., Renoth S., et al. Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial. Cancer Immunol Immunother 51 (2002) 637-644
27. Azuma T., Horie S., Tomita K., et al. Dendritic cell immunotherapy for patients with metastatic renal cell carcinoma: University of Tokyo experience. Int J Urol 9 (2002) 340-346
28. Holtl L., Zelle-Rieser C., Gander H., et al. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res 8 (2002) 3369-3376
29. Oosterwijk-Wakka J.C., Tiemessen D.M., Bleumer I., et al. Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study. J Immunother 25 (2002) 500-508
30. Su Z., Dannull J., Heiser A., et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res 63 (2003) 2127-2133
31. Gitlitz B.J., Belldegrun A.S., Zisman A., et al. A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. J Immunother 26 (2003) 412-419
32. Marten A., Renoth S., Heinicke T., et al. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum Gene Ther 14 (2003) 483-494
33. + monocyte-derived dendritic cells in patients with metastatic renal cell carcinoma treated with dendritic cell vaccines. J Clin Immunol 24 (2004) 86-96
34. Pandha H.S., John R.J., Hutchinson J., et al. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study. BJU Int 94 (2004) 412-418
35. Avigan D., Vasir B., Gong J., et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res 10 (2004) 4699-4708
36. Barbuto J.A., Ensina L.F., Neves A.R., et al. Dendritic cell-tumor cell hybrid vaccination for metastatic cancer. Cancer Immunol Immunother 53 (2004) 1111-1118
37. Dannull J., Su Z., Rizzieri D., et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115 (2005) 3623-3633
38. Holtl L., Ramoner R., Zelle-Rieser C., et al. Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide. Cancer Immunol Immunother 54 (2005) 663-670
39. Wierecky J., Muller M.R., Wirths S., et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 66 (2006) 5910-5918
40. Bleumer I., Tiemessen D.M., Oosterwijk-Wakka J.C., et al. Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9-peptide-pulsed mature dendritic cells. J Immunother 30 (2007) 116-122
41. Matsumoto A., Haraguchi K., Takahashi T., et al. Immunotherapy against metastatic renal cell carcinoma with mature dendritic cells. Int J Urol 14 (2007) 277-283
42. Kim J.H., Lee Y., Bae Y.S., et al. Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma. Clin Immunol 125 (2007) 257-267
43. Avigan D.E., Vasir B., George D.J., et al. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother 30 (2007) 749-761
44. Wei Y.C., Sticca R.P., Li J., et al. Combined treatment of dendritoma vaccine and low-dose interleukin-2 in stage IV renal cell carcinoma patients induced clinical response: a pilot study. Oncol Rep 18 (2007) 665-671
45. Uemura H., Fujimoto K., Tanaka M., et al. A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma. Clin Cancer Res 12 (2006) 1768-1775
46. Iiyama T., Udaka K., Takeda S., et al. WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinoma. Microbiol Immunol 51 (2007) 519-530
47. Suekane S., Nishitani M., Noguchi M., et al. Phase I trial of personalized peptide vaccination for cytokine-refractory metastatic renal cell carcinoma patients. Cancer Sci 98 (2007) 1965-1968
48. Patel P.M., Sim S., O'Donnell D.O., et al. An evaluation of a preparation of Mycobacterium vaccae (SRL172) as an immunotherapeutic agent in renal cancer. Eur J Cancer 44 (2008) 216-223
49. Wood C., Srivastava P., Bukowski R., et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 372 (2008) 145-154
50. Jonasch E., Wood C., Tamboli P., et al. Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. Br J Cancer 98 (2008) 1336-1341
51. Kim H.L., Sun X., Subjeck J.R., and Wang X.Y. Evaluation of renal cell carcinoma vaccines targeting carbonic anhydrase IX using heat shock protein 110. Cancer Immunol Immunother 56 (2007) 1097-1105
52. Hernandez J.M., Bui M.H., Han K.R., et al. Novel kidney cancer immunotherapy based on the granulocyte-macrophage colony-stimulating factor and carbonic anhydrase IX fusion gene. Clin Cancer Res 9 (2003) 1906-1916
53. Shuch B., Li Z., and Belldegrun A.S. Carbonic anhydrase IX and renal cell carcinoma: prognosis, response to systemic therapy, and future vaccine strategies. BJU Int 101 Suppl 4 (2008) 25-30
54. Yang J.C., Hughes M., Kammula U., et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 30 (2007) 825-830